این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Journal of Pharmaceutical Care، جلد ۱۲، شماره ۳، صفحات ۱۹۹-۲۰۲
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Standard dose Cytarabine-Induced Encephalopathy in an Acute Myeloid Leukemia Patient: A Case Report
چکیده انگلیسی مقاله The mainstay of treatment for acute myeloid leukemia (AML), cytarabine, is known to induce encephalopathy, usually at high doses. During induction chemotherapy, a 38-year-old woman with non-M3 AML experienced encephalopathy following the administration of standard-dose cytarabine. The patient's mental state deteriorated, and she exhibited symptoms of physical weakness, confusion, and lethargy. There were no abnormalities in the brain parenchyma discovered by a CT scan. After a diagnosis of cytarabine-induced encephalopathy, cytarabine treatment was abruptly discontinued. Levetiracetam was used for managing seizures, intravenous hydration, and medication management, all of which were put into place as supportive measures. Over the next few days, the patient's mental state got better, and ten days later, she was fully conscious again. The encephalopathy and cytarabine were likely related, according to the Naranjo scale. Cytarabine was not reintroduced due to the patient's recovery and to prevent any potential problems. Rather, an alternate treatment regimen consisting of etoposide and mitoxantrone was initiated. This case emphasizes how crucial it is to take cytarabine-induced encephalopathy into account as a possible side effect when treating AML, even at lower doses of the medication. to minimize patient morbidity and ensure a successful treatment course, healthcare practitioners need to be on alert for signs and symptoms of this condition. Early detection and rapid cessation of cytarabine medication are critical steps in this regard.
کلیدواژه‌های انگلیسی مقاله
نویسندگان مقاله | Mehrshad Ebrahimpour
Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.


| Samin Ghorbani Moghadam
Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.


| Mostafa Kamandi
Department of Internal Medicine, Faculty of Medicine, Mashhad University of Medical Sciences Mashhad Iran.


| Omid Arasteh
Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
نشانی اینترنتی https://jpc.tums.ac.ir/index.php/jpc/article/view/739
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات